#MRUS

Halper Sadeh LLC Urges Shareholders of HSII, MRUS, and ATXS to Know Their Rights Halper Sadeh LLC is reaching out to shareholders of Heidrick, Merus, and Astria to discuss potential violations of securities laws and shareholder rights.

3 months ago

#HALO #MRUS Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

www.stocktitan.net/news/HALO/merus-and-halo...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Halper Sadeh LLC Urges Shareholders of HSII, MRUS, and ATXS to Know Their Rights #USA #New_York #Halper_Sadeh_LLC #HSII #MRUS

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Class Action Firm Monteverde Investigates Critical Mergers for Shareholders Monteverde & Associates PC is investigating significant mergers involving MRUS, HSII, PRO, and PBBK, advocating for shareholder rights.

Class Action Firm Monteverde Investigates Critical Mergers for Shareholders #USA #New_York #Monteverde_&_Associates #HSII #MRUS

0 0 0 0

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model Genmab (Nasdaq: GMAB) has announced its plans to acquire Merus (Nasdaq: MRUS) in an all-cash transaction valued at approximately USD 8.0 billion, or USD 97.00 per share. The acquisition represents a 41% premium over Merus' closing price on September 26, 2025.The strategic acquisition brings petosemtamab, a late-stage oncology asset with two FDA Breakthrough Therapy Designations for head and neck cancer, into Genmab's portfolio. The Phase 3 asset showed promising Phase 2 data at ASCO 2025, with superior overall response rates and progression-free survival compared to standard care. Genmab expects potential product launch in 2027, with projected annual sales of $1+ billion by 2029.The transaction will be funded through cash and $5.5 billion in non-convertible debt. Genmab aims to achieve gross leverage below 3x within two years post-closing. The deal is expected to close by early Q1 2026 and become EBITDA accretive by end of 2029.

5 months ago

#GMAB #MRUS Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

www.stocktitan.net/news/GMAB/genmab-to-acqu...

0 0 0 0

Merus N.V. Announces Proposed Public Offering of Common Shares Merus N.V. (MRUS), an oncology company specializing in multispecific antibodies and antibody drug conjugates, has announced a proposed public offering of common shares. The offering includes a 30-day option for underwriters to purchase up to an additional 15% of shares. The company plans to use the proceeds to advance clinical development of product candidates, fund preclinical research, and support working capital needs. The offering is being managed by multiple firms including Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities, Truist Securities, and LifeSci Capital as joint book-running managers, with Van Lanschot Kempen as lead manager. The offering will be conducted through a shelf registration statement on Form S-3 filed with the SEC.

9 months ago

#MRUS Merus N.V. Announces Proposed Public Offering of Common Shares

www.stocktitan.net/news/MRUS/merus-n-v-anno...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

9 months ago

Original post on benzinga.com

Merus Stock Surges Over 35% On Strong Phase 2 Cancer Trial Results: What's Going On? Merus N....

www.benzinga.com/25/05/45594630/merus-sto...

#MRUS #News #why #it's #moving #Movers […]

[Original post on benzinga.com]

0 0 0 0

Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC Merus (NASDAQ: MRUS) announced promising interim data from its phase 2 trial of petosemtamab combined with pembrolizumab for head and neck squamous cell carcinoma (HNSCC). The study showed a 63% response rate among 43 evaluable patients, including 6 complete responses and 21 partial responses. Key highlights include: - 79% overall survival rate at 12 months - 9 months median progression-free survival - Responses observed across PD-L1 levels - 14 responding patients still on treatment The treatment combination was generally well-tolerated, with Grade ≥3 treatment-emergent adverse events occurring in 60% of patients. Infusion-related reactions were reported in 38% of patients, mainly during first infusion. The data suggests potential superiority over pembrolizumab monotherapy, positioning petosemtamab as a possible future standard of care in head and neck cancer. Merus expects to share top-line interim readout of phase 3 trials in 2026.

9 months ago

#MRUS Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

www.stocktitan.net/news/MRUS/merus-petosemt...

0 0 0 0

Breakthrough: New Cancer Drug Petosemtamab Reveals 3 Ways to Fight Aggressive Tumors, Journal Study Shows Novel cancer antibody demonstrates three distinct mechanisms against resistant tumors. Phase 3 trials ongoing in head & neck cancer, colorectal studies advancing. See full data.

10 months ago

#MRUS Merus Announces the Journal Publication of Petosemtamab Mechanism of Action

www.stocktitan.net/news/MRUS/merus-announce...

0 0 0 0

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update Merus (MRUS) reported Q1 2025 financial results and provided business updates. The company's petosemtamab drug shows promising progress with two phase 3 trials expected to be substantially enrolled by year-end 2025. The company plans to present updated interim phase 2 data for petosemtamab in combination with pembrolizumab at the 2025 ASCO Annual Meeting. Financially, Merus reported $638 million in cash and equivalents, expected to fund operations into 2028. Q1 2025 revenue increased by $18.6 million compared to Q1 2024, primarily due to commercial material revenue. However, operating expenses increased significantly, with R&D expenses up by $41.5 million and G&A expenses up by $6.0 million. The company reported a net loss of $96.47 million for Q1 2025, compared to a $34.46 million loss in Q1 2024.

10 months ago

#MRUS Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

www.stocktitan.net/news/MRUS/merus-announce...

0 0 0 0

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update Merus (NASDAQ: MRUS) announced financial results and business updates for Q4 and full year 2024. Key highlights include the FDA approval of BIZENGRI® for NRG1+ pancreatic adenocarcinoma and NSCLC patients, and two Breakthrough Therapy designations for petosemtamab.The company is advancing two Phase 3 trials for petosemtamab: LiGeR-HN1 (in combination with pembrolizumab for 1L PD-L1+ r/m HNSCC) and LiGeR-HN2 (monotherapy in 2/3L r/m HNSCC), both expected to be substantially enrolled by year-end 2025. Interim data showed a 67% response rate in 1L HNSCC combination therapy and 36% response rate in 2L+ monotherapy.Financial position remains strong with $724.0 million in cash, cash equivalents and marketable securities as of December 31, 2024, expected to fund operations into 2028.

1 year ago

#MRUS Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

www.stocktitan.net/news/MRUS/merus-announce...

0 0 0 0

Revolutionary Cancer Treatment: 67% Response Rate Earns FDA Breakthrough Status for Head & Neck Cancer Drug Merus's petosemtamab receives FDA breakthrough status after showing 67% response rate in head & neck cancer trial, accelerating path to potential approval.

1 year ago

#MRUS Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

www.stocktitan.net/news/MRUS/petosemtamab-g...

0 0 0 0

Landmark Cancer Treatment: Merus's Bizengri Shows Promising Results for Untreatable Lung & Pancreatic Cancers Merus's Bizengri demonstrates efficacy in phase 2 trial for NRG1 fusion-positive cancers, becoming first approved treatment for specific pancreatic and lung cancers. Results published in NEJM.

1 year ago

#MRUS New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

www.stocktitan.net/news/MRUS/new-england-jo...

0 0 0 0

Merus and Biohaven Partner to Develop Next-Generation Cancer-Fighting ADC Therapies Strategic collaboration combines Merus' Biclonics® platform with Biohaven's ADC technology to develop three novel bispecific antibody drug conjugates for cancer treatment.

1 year ago

#MRUS Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

www.stocktitan.net/news/MRUS/merus-and-bioh...

0 0 0 0

Merus Launches Phase 2 Trial for Novel Cancer Drug Petosemtamab in Advanced Colorectal Cancer Merus initiates Phase 2 study of petosemtamab, a promising bispecific antibody showing superior preclinical activity vs. standard therapy in metastatic colorectal cancer.

1 year ago

#MRUS Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

www.stocktitan.net/news/MRUS/merus-announce...

0 0 0 0

Merus's Cancer Drug Shows 36% Response Rate in Head & Neck Cancer Trial, Including Complete Responses | MRUS Stock News Latest clinical data reveals promising efficacy for Merus's petosemtamab in head & neck cancer, with 36% response rate and complete responses in high-dose cohort.

1 year ago

#MRUS Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

#StockMarket #news #stocks

www.stocktitan.net/news/MRUS/merus-petosemt...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

News; ( NASDAQ: #MRUS ) Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

#StockMarket #News

0 0 0 0

Merus Partners with PTx for U.S. Rights to Novel Cancer Drug Zeno, FDA Review Underway | MRUS Stock News Merus signs exclusive U.S. licensing deal with Partner Therapeutics for zenocutuzumab in NRG1+ cancers. Deal includes upfront payment plus milestones as FDA reviews first targeted therapy.

1 year ago

#MRUS Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

#cancer #investing #news

www.stocktitan.net/news/MRUS/merus-and-part...

0 0 0 0

Merus's Petosemtamab Shows 40.4% Response Rate in Head & Neck Cancer Trial | MRUS Stock News Latest clinical data reveals Merus's cancer drug achieves 40.4% response rate in head & neck cancer patients, with 12.5-month median survival and favorable safety profile at 1500mg dose.

1 year ago

#MRUS Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

#StockMarket #stocks #news

www.stocktitan.net/news/MRUS/merus-announce...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NASDAQ: #MRUS ) Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

#StockMarket #News

1 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #MRUS ) Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

#StockMarket #News

0 0 0 0

1 year ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #KALV 52% OTM
2. #MRUS 45% OTM
3. #RUM 40% OTM
4. #CVNA 39% OTM
5. #EH 39% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 year ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#KALV, #CLSK, #CVNA, #MRUS, #TPST

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 year ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #KALV 52% OTM
2. #CGC 48% OTM
3. #CLSK 48% OTM
4. #CVNA 46% OTM
5. #MRUS 45% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0